91373-91-0

Upstream product

• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 33697-81-3 (3-chloro-4-hydroxy-phenyl)-acetic acid 

Downstream Products

• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 870289-05-7 [3-chloro-4-(3,5-dibromobenzylsulfanyl)phenyl]acetic acid methyl ester 
• 890137-68-5 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethylsulfanyl)-3-chloro-phenyl]-acetic acid methyl ester 
• 91361-79-4 3-chloro-4-sulphanyl-phenylacetic acid methyl ester 
• 194792-52-4 methyl 3-chloro-4-(3-bromopropylthio)-phenylacetate 
• 194608-87-2 {3-chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194855-43-1 methyl 3-chloro-4-(3-(3-ethyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetate 
• 194608-84-9 methyl 3-chloro-4-(3-(2-propyl-3-hydroxy-4-propionylphenoxy)propylthio)phenylacetate 
• 194608-93-0 methyl 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetate 
• 194608-85-0 {3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 709028-29-5 (3-Chloro-4-{3-[3-hydroxy-2-propyl-4-(2,2,2-trifluoro-acetyl)-phenoxy]-propylsulfanyl}-phenyl)-acetic acid methyl ester 
• 709028-30-8 {3-Chloro-4-[3-(3-hydroxy-2-propyl-4-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 393186-02-2 3-chloro-4-[2-[[(1,1-dimethylethoxy)carbonyl]-amino]-ethylthio]benzeneacetic acid methyl ester 

Relevant academic research and scientific papers

1,3,5-Trisubstituted aryls as highly selective PPARδ agonists

A series of highly potent and selective PPARδ agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes up to 10 μM, making it a useful tool in studying the biological effects of selective PPARδ activation.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ .

Phenylacetic acid derivatives as hPPAR agonists

Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. F

Identification of a series of PPARγ/δ dual agonists via solid-Phase parallel synthesis

We have developed a general solid-phase synthesis for identification of PPAR ligands. Synthesis of a 480-member library led to the identification of a potent PPARγ/δ dual agonist 23. Compound 23 showed good plasma exposure in rats and demonstrated antihyp